Flare Roller Coaster for People Living with Arthritis and Connective Tissue Diseases
The Next Rheumatology Flare Roller Coaster workshop will be held on Saturday 3rd February 2018, from 09:30 -13:00.
Venue: Fracture Clinic – C Level, Queen Alexandra Hospital, Cosham PO6 3LY
Places are limited so please register early.
To book your place or receive more information, email: rheumatology.conference@porthosp.nhs.uk or telephone 02392286935
For frequently asked questions about our Flare Rollercoaster workshop, please see our leaflet [PDF].
If you have arthritis or a connective tissue disease, the festive period can be tough.…
Read more of this article

This exciting initiative aims to support the development of assistive products that help people living with arthritis and musculoskeletal conditions to live well, to help people be independent and to be in control of their lives as much as possible.…
The British Orthopaedic Association (BOA) is pleased to announce the recent publication of four revised commissioning guides with the Royal College of Surgeons of England. These NICE-accredited guides set out best practice care pathways to assist CCGs in designing optimal care for their populations. We are extremely grateful to all those involved in the rigorous development and accreditation processes. The guides, which can be found here, are:


In July LUPUS UK released the newest edition in their range of publications, ‘LUPUS: Bone Health & Osteoporosis’.
The current delay to diagnosis of ankylosing spondylitis (AS) stands at 8.5 years. NASS are committed to reducing this delay to diagnose. There are many factors impacting on this delay but an important issue is the recognition of AS in primary care and prompt referral on to rheumatology.
On 10th July 2017, NICE issued a new Technology Appraisal (TA) for bisphosphonates which links the recommendations for drug treatments to advice on fracture risk assessment outlined in their earlier guidance. The TA is not intended to provide treatment thresholds but offers recommendations on cost-effective use of bisphosphonates when using fracture risk assessment as described in their guideline